Source: Incyte press release. September 17, 2025.
From EADV: Povorcitinib Maintains Efficacy Through 24 Weeks in STOP-HS Program
09/19/2025
KEY TAKEAWAYS
Data from the STOP-HS study presented at EADV 2025 showed almost 60% of patients receiving povorcitinib achieved HiSCR50 at week 24.
Meaningful pain reduction was observed by week 3 and sustained through week 24.
New 24-week results from the phase 3 STOP-HS trial program suggest that investigational oral JAK1 inhibitor povorcitinib provided sustained clinical benefits in adults with moderate to severe hidradenitis suppurativa (HS), according to findings presented at the 2025 European Association of Dermatology and Venereology (EADV) 2025 Congress.
“HS remains a challenging and often debilitating condition and many patients are in need of new, well-tolerated and effective therapies that address prominent signs and symptoms of the disease, including inflammatory lesions and pain,” said Pablo J. Cagnoni, MD President and Head of Research and Development, Incyte, in a press report released after the data were presented. “We are pleased to share these late-breaking data with the dermatology community, including health care providers and people with HS. The STOP-HS abstract will provide additional detail on povorcitinib as an oral treatment option for HS and its ability to rapidly improve symptoms, with continued clinical responses seen through 24 weeks.”
According to a press release from the manufacturer released after the data were unveiled, nearly 60% of efficacy-evaluable patients receiving povorcitinib (45 mg or 75 mg) achieved HiSCR50 (defined as a ≥ 50% reduction in total abscess and inflammatory nodule count with no increase in abscesses or draining tunnels) by week 24 (see Table). Higher thresholds of response were also reported, with HiSCR75 in up to 40.3%, HiSCR90 in up to 27.7%, and complete response (HiSCR100) in up to 21.3% of patients. Skin pain improved as early as week 3 and was sustained through week 24, with 62% to 70% of patients reporting mild or no pain. Between 39.0% to 50.6% of patients achieved a 100% reduction in draining tunnels by week 24.
Table. Percentage of povorcitinib-treated patients achieving HiSCR50 vs placebo at 12 and 12 weeks
STOP-HS1 | 12-week 45 mg: 40.2% vs. 29.7% [P = 0.024] 24-week 45 mg: 52.9%-64.0% 12-week 75 mg: 40.6% vs. 29.7% [P = 0.0214] 24-week 75 mg: 50.0%-62.7% | |
STOP-HS2 | 12-week 45 mg: 42.3% vs. 28.6% [P = 0.0035] 24-week 45 mg: 57.1%-58.0% 12-week 75 mg: 42.3% vs. 28.6% [P = 0.0033] 24-week 75 mg: 56.3%-58.5% |
“HS is a complex and often misunderstood condition that can profoundly affect patients’ daily lives,” said Dr. Martina Porter, STOP-HS study investigator, Assistant Professor of Dermatology at Harvard Medical School and Vice Chair for Research and Academics, Department of Dermatology at Beth Israel Deaconess Medical Center, in the news release. “Data from the STOP-HS clinical trial program highlight the potential of povorcitinib to address key signs and symptoms for those living with HS, and it is encouraging to see advancements in potential new, effective treatment options for this patient community.”